Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission

Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12100-4. doi: 10.1073/pnas.92.26.12100.

Abstract

To prevent mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission, it is important to identify its determinants. Because HIV-1 RNA levels can be reduced by antiviral therapy, we examined the role of maternal plasma HIV-1 RNA level in mother-to-child transmission. We used quantitative competitive PCR to measure HIV-RNA in 30 infected pregnant women and then followed their infants prospectively; 27% of the women transmitted HIV-1 to their infants and maternal plasma HIV-1 RNA level correlated strikingly with transmission. Eight of the 10 women with the highest HIV-1 RNA levels at delivery (190,400-1,664,100 copies per ml of plasma) transmitted, while none of the 20 women with lower levels (500-155,800 copies per ml) did (P = 0.0002). Statistical analysis of the distribution of HIV-1 RNA loads in these 30 women projected a threshold for mother-to-child transmission in a larger population; the probability of a woman with a viral RNA level of < or = 100,000 copies per ml not transmitting is predicted to be 97%. Examination of serial HIV-1 RNA levels during pregnancy showed that viral load was stable in women who did not initiate or change antiviral therapy. These data identify maternal plasma HIV-1-RNA level as a major determinant of mother-to-child transmission and suggest that quantitation of HIV-1 RNA may predict the risk of transmission.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acquired Immunodeficiency Syndrome / blood
  • Acquired Immunodeficiency Syndrome / prevention & control
  • Acquired Immunodeficiency Syndrome / transmission*
  • Adolescent
  • Adult
  • Delivery, Obstetric
  • Drug Resistance, Microbial
  • Female
  • Gestational Age
  • HIV-1 / isolation & purification*
  • Humans
  • Infant, Newborn
  • Infectious Disease Transmission, Vertical*
  • Labor, Obstetric
  • Polymerase Chain Reaction / methods*
  • Pregnancy
  • Pregnancy Complications, Infectious / blood*
  • Pregnancy Complications, Infectious / virology
  • Pregnancy Trimester, Second
  • Pregnancy Trimester, Third
  • Prospective Studies
  • RNA, Viral / blood*
  • Zidovudine / therapeutic use

Substances

  • RNA, Viral
  • Zidovudine